Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP4 | P15090 | 2/20 | 0.50 |
| ▸ | FABP3 | P05413 | 1/20 | 0.50 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | F10 | P00742 | 7/20 | 0.41 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | PLG | P00747 | 9/20 | 0.39 |
| ▸ | PLAU | P00749 | 9/20 | 0.39 |
| ▸ | F2 | P00734 | 6/20 | 0.39 |
| ▸ | ST14 | Q9Y5Y6 | 6/20 | 0.39 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11440688 | 0.86 | FABP4 (0.43) | FABP4FABP3FABP5GAATDP1 | |
| SCHEMBL3684371 | 0.85 | FABP4 (0.51) | FABP4FABP3FABP5GAATDP1 | |
| SCHEMBL8602352 | 0.83 | FABP4 (0.49) | FABP4FABP3FABP5GAATDP1 | |
| SCHEMBL23052183 | 0.81 | FABP4 (0.51) | FABP4FABP3FABP5GAACYP3A4 | |
| SCHEMBL6323293 | 0.81 | FABP4 (0.50) | FABP4FABP3FABP5GAATDP1 | |
| SCHEMBL6020579 | 0.80 | FABP4 (0.46) | FABP4FABP3FABP5GAATDP1 | |
| SCHEMBL18553823 | 0.79 | CA12 (0.48) | FABP4FABP3FABP5GAATDP1 | |
| SCHEMBL675038 | 0.78 | FABP4 (0.58) | FABP4FABP3FABP5GAATDP1 | |
| SCHEMBL21922801 | 0.77 | FABP4 (0.62) | FABP4FABP3FABP5GAATDP1 | |
| SCHEMBL17611222 | 0.76 | FABP3 (0.53) | FABP4FABP3FABP5GAATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10851126-B2 | Complexes and methods for their preparation | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2020-12-01 | — | — | US | disclosed |
| US-10851126-B2 | Complexes and methods for their preparation | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2020-12-01 | — | — | US | disclosed |
| EP-3194364-B1 | METHODS FOR PREPARATION OF AMINE COMPOUNDS AND INTERMEDIATES THEREOF | JOHNSON MATTHEY PLC (GB) | 2020-11-04 | — | — | EP | disclosed |
| EP-3194364-B1 | METHODS FOR PREPARATION OF AMINE COMPOUNDS AND INTERMEDIATES THEREOF | JOHNSON MATTHEY PLC (GB) | 2020-11-04 | — | — | EP | disclosed |
| CN-106715388-B | Complex and preparation method thereof | 庄信万丰股份有限公司 | 2020-01-03 | — | — | CN | disclosed |
| US-20170275317-A1 | COMPLEXES AND METHODS FOR THEIR PREPARATION | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2017-09-28 | — | — | US | disclosed |
| US-20170275317-A1 | COMPLEXES AND METHODS FOR THEIR PREPARATION | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2017-09-28 | — | — | US | disclosed |
| US-20170275317-A1 | COMPLEXES AND METHODS FOR THEIR PREPARATION | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2017-09-28 | — | — | US | disclosed |
| EP-3194364-A1 | COMPLEXES AND METHODS FOR THEIR PREPARATION | Johnson Matthey Public Limited Company (GB) | 2017-07-26 | — | — | EP | disclosed |
| WO-2016042298-A1 | COMPLEXES AND METHODS FOR THEIR PREPARATION | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2016-03-24 | — | — | WO | disclosed |
| WO-2016042298-A1 | COMPLEXES AND METHODS FOR THEIR PREPARATION | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2016-03-24 | — | — | WO | disclosed |
| WO-2015140575-A1 | ENZYME DETECTION METHOD | ATLAS GENETICS LIMITED (GB) | 2015-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170275317-A1 | COMPLEXES AND METHODS FOR THEIR PREPARATION | CYCS, COX6C, SOD1 | FABP4 2780/4885FABP3 1603/4885FABP5 926/4885 |
| US-10851126-B2 | Complexes and methods for their preparation | CYCS, COX6C, SOD1 | FABP4 2780/4885FABP3 1603/4885FABP5 926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.